Design Therapeutics, Inc.
DSGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807120
No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Design Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 96 | 97 | +1 |
| Shares | 38.7M | 38.8M | +94.7K (+0.2%) |
| Value | $223.3M | $244.4M | +$21.1M (+9.5%) |
New holders (10)
Institutions that held Design Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| RTW Investments, LP | 1,563,031 | $9.85M | 0.19% |
| Candriam Luxembourg S.C.A. | 185,000 | $1.17M | 0.01% |
| Bank of Montreal | 99,240 | $629.2K | 0.00% |
| Prudential Financial Inc | 26,215 | $165.2K | 0.00% |
| Algert Global LLC | 19,430 | $122.4K | 0.01% |
| Balyasny Asset Management LLC | 18,499 | $116.5K | 0.00% |
| Corton Capital Inc. | 17,323 | $109.1K | 0.05% |
| Jacobs Levy Equity Management, Inc | 16,100 | $101.4K | 0.00% |
| Walleye Capital LLC | 11,138 | $70.2K | 0.00% |
| XTX Topco Ltd | 10,799 | $68.0K | 0.01% |
Sold out (9)
Institutions that held Design Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Ergoteles LLC | 177,337 | $1.02M |
| Centiva Capital, LP | 23,572 | $136.0K |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd. | 19,306 | $111.4K |
| SG Americas Securities, LLC | 15,040 | $87.0K |
| Occudo Quantitative Strategies LP | 12,652 | $73.0K |
| Atom Investors LP | 11,890 | $68.6K |
| Ellevest, Inc. | 100 | $577 |
| EverSource Wealth Advisors, LLC | 79 | $456 |
| Nisa Investment Advisors, LLC | 17 | $0 |